Spruce Biosciences (SPRB) announced the company’s new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy for ...

Merida Biosciences has emerged from Third Rock Ventures with $121 million in first-round financing for a pipeline of drugs ...

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need ...

Q1 2023 Earnings Call Transcript April 15, 2025 Spruce Biosciences, Inc. misses on earnings expectations. Reported EPS is $-0 ...

The South San Francisco biotech has acquired rights to tralesinidase alfa, an enzyme replacement therapy (ERT) for the ...

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...

GeneVentiv Therapeutics, a gene therapy company, today announced it has signed a global licensing agreement with Duke ...

Gaucher disease is a rare inherited condition caused by the body’s inability to break down a fatty substance called glucocerebroside. This happens due to a lack of an important enzyme known ...

The Argentina inborn errors of protein metabolism (IEPM) market was valued at US$ 268.2 million in 2023 and is expected to achieve a market valuation of US$ 664.0 million by 2032. This impressive ...

Today, the Born and Schneider family announced the launch of Helen’s Pink Sky Foundation, a new nonprofit dedicated to accelerating research, raising awareness, and improving the lives of those ...

Chris Bloore, Labour MP for Redditch and the Villages, is calling for "urgent" government action over the "unbearable ...